675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, X1
Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
Investor Presentation
Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Other Events
To Present at the H.C. Wainwright 28th Annual Global Investment Conference
Amended material disclosure
Appoints Michael J. Grissinger to Board of Directors
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Registration of Securities under Section 12(g)